Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD33 CAR NK cells
- Development stage
- Unknown
- Lead developer
- Medical Center of Hematology, Xinqiao Hospital of Army Medical University
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD33 CAR NK cells are an investigational cell therapy designed to treat relapsed/refractory acute myeloid leukemia (r/r AML). This therapy utilizes natural killer (NK) cells engineered with a Chimeric Antigen Receptor (CAR) specifically targeting the CD33 antigen, which is widely expressed on AML cells. The CAR enables the NK cells to recognize and bind to AML cells, leading to their destruction. Developed by Ruihao Huang and colleagues at the Medical Center of Hematology, Xinqiao Hospital of Army Medical University, in Chongqing, China, this therapy aims to overcome challenges associated with 'on target, off tumor' side effects seen with other myeloid malignancy targets by leveraging the safety profile of NK cells. Early clinical findings presented at the 2022 EHA Annual Meeting showed efficacy and safety in a small cohort of r/r AML patients, with some achieving MRD-negative complete response.
- Other names
- anti-CD33 CAR-NK cellsanti-CD-33 CAR-NK cellsanti-CD 33 CAR-NK cells
02
Targets
CD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on CD33 CAR NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD33 CAR NK cells.